We are working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients SPOTLIGHT Curis Corporate Presentation View our Current Corporate Presentation here. Curis - VISTA PRESS RELEASES Nov 09 | 2021 Curis Reports Third Quarter 2021 Financial Results and Business Update » Nov 09 | 2021 Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting » Nov 08 | 2021 Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes » PIPELINE Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Drug Indication Stage Heme Malignancies CA-4948* IRAK4 MYD88/TLR-altered Lymphoma (NHL) Clinical Activity CA-4948* IRAK4 IRAK4L-expressing Leukemia (AML/MDS) Clinical Activity Fimepinostat HDAC/PI3K MYC-altered Cancers Clinical Activity Immune Checkpoint Inhibitors CI-8993** VISTA VISTA-expressing Cancers Safety CA-327* TIM3/PDL1 PDL1/TIM3-expressing Cancers Proof of Principle CA-170* VISTA/PDL1 PDL1/VISTA-expressing Cancers Clinical Activity Approved Drug Erivedge*** Hedgehog Basal Cell Carcinoma Commercial * IP licensed from Aurigene ** Option to license IP from ImmuNext *** IP licensed to Genentech (Curis receives royalty income) © Curis, Inc. 2021 - All Rights Reserved Terms of Use Privacy Policy , in accordance with our privacy policies. I Understand ABOUT COLLABORATIONS PATIENTS PIPELINE INVESTORS CAREERS CONTACT

COMMITTEE COMPOSITION * Independent Director AUDIT NOMINATING AND GOVERNANCE COMPENSATION MARTYN D. GREENACRE1* KENNETH I. KAITIN, PH.D.* LORI A. KUNKEL M.D.* MARC RUBIN, M.D.* JAMES DENTZER Chair Member 1Chair of the Board *Independent Director © Curis, Inc. 2019 - All Rights Reserved Terms of UsePrivacy Policy , in accordance with our privacy policies. I Understand

COMPANY OVERVIEW We are a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. The symbol included above the ‘i’ in Curis is known as a fermata. A fermata is used in written notes of musical pieces to indicate the prolongation of a note, a rest of indefinite duration, or the closing of a piece. At Curis, we apply this meaning to cancer, by developing novel therapies for slowing or preventing the progression of cancer and prolonging life – or closing and curi͒ng cancer. © Curis, Inc. 2021 - All Rights Reserved Terms of Use Privacy Policy , in accordance with our privacy policies. I Understand ABOUT COLLABORATIONS PATIENTS PIPELINE INVESTORS CAREERS CONTACT